<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03277690</url>
  </required_header>
  <id_info>
    <org_study_id>COR-2017-01</org_study_id>
    <nct_id>NCT03277690</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.</brief_title>
  <official_title>A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cortendo AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cortendo AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration&#xD;
      study in subjects with endogenous CS previously treated with single-arm, open-label&#xD;
      levoketoconazole that will assess efficacy, safety, tolerability, and pharmacokinetics of&#xD;
      levoketoconazole.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration&#xD;
      study in subjects with endogenous CS that will assess efficacy, safety, tolerability, and PK&#xD;
      of levoketoconazole. There are two populations (cohorts) of subjects: (1) subjects which were&#xD;
      previous levoketoconazole study completers and (2) subjects that are levoketoconazole&#xD;
      treatment naïve subjects.&#xD;
&#xD;
      Study methodology varies by cohort prior to randomization only. Following initial screening&#xD;
      (washout as needed) and Dose Titration and Maintenance Periods, as applicable, this study&#xD;
      will be conducted in two double-blind phases (a Withdrawal Phase and a Restoration Phase).&#xD;
      The levoketoconazole-naïve cohort will need to go through the Dose Titration and Maintenance&#xD;
      Phase. The longest anticipated total study participation duration is approximately 51 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2017</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with loss of therapeutic response to levoketoconazole upon withdrawing to placebo compared with the proportion of subjects with loss of therapeutic response upon continuing treatment with levoketoconazole.</measure>
    <time_frame>max. 9.5 weeks</time_frame>
    <description>Urinary free cortisol (UFC) level measurement</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Endogenous Cushing's Syndrome</condition>
  <arm_group>
    <arm_group_label>Levoketoconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind withdrawal phase: Levoketoconazole (up to a dose of 1200 mg); Double blind restoration phase: Levoketoconazole plus Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double blind withdrawal phase: Placebo; Double blind restoration phase: Placebo plus Levoketoconazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levoketoconazole</intervention_name>
    <description>During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.&#xD;
During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo.</description>
    <arm_group_label>Levoketoconazole</arm_group_label>
    <other_name>COR-003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>During the double-blind Withdrawal Phase, patients will receive placebo tablets.&#xD;
During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        SONICS STUDY COMPLETERS:&#xD;
&#xD;
        Completed the final SONICS visit (M12) and have demonstrated maintenance of clinical&#xD;
        response on a stable Therapeutic Dose of levoketoconazole for at least 12 weeks prior to&#xD;
        study entry.&#xD;
&#xD;
        ALL OTHERS:&#xD;
&#xD;
          -  Confirmed newly diagnosed, persistent or recurrent endogenous Cushing's syndrome of&#xD;
             any etiology, except secondary to malignancy (including pituitary or adrenal&#xD;
             carcinoma).&#xD;
&#xD;
          -  Elevated mean 24-hour UFC levels at least 1.5X upper limit of the normative range of&#xD;
             the study's central laboratory assay and from a minimum of three measurements from&#xD;
             adequately collected urine.&#xD;
&#xD;
          -  Presence of abnormal values from at least one of these two diagnostic tests:&#xD;
&#xD;
               -  Abnormal Dexamethasone Suppression Test (DST) OR&#xD;
&#xD;
               -  Elevated late night salivary cortisol concentrations (at least two measurements)&#xD;
                  each greater than the upper limit of the study's central laboratory normative&#xD;
                  range&#xD;
&#xD;
          -  Non-candidates for CS-specific surgery, refuse surgery or surgery will be delayed&#xD;
             until after study completion and agree to complete this study prior to surgery.&#xD;
&#xD;
          -  If post-surgical for CS-specific surgery, then no significant post-operative sequelae&#xD;
             remain and the risk of such sequelae is considered negligible.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Subjects will be excluded from the study if ANY of the following criteria are met (NOTE:&#xD;
        exclusion criteria apply to and must be assessed in both cohorts):&#xD;
&#xD;
          -  Enrolled in SONICS but have not completed SONICS through Visit M12.&#xD;
&#xD;
          -  Pseudo-Cushing's syndrome based on assessment of the Investigator.&#xD;
&#xD;
          -  Cyclic Cushing's syndrome with multi-week periods of apparent spontaneous CS&#xD;
             remission.&#xD;
&#xD;
          -  Non-endogenous source of hypercortisolism, including pharmacological corticosteroids&#xD;
             or ACTH.&#xD;
&#xD;
          -  Radiotherapy of any modality directed against the source of hypercortisolism within&#xD;
             the last 5 years.&#xD;
&#xD;
          -  Treatment with mitotane within 6 months of enrollment.&#xD;
&#xD;
          -  History of malignancy, including adrenal or pituitary carcinomas (other than low-risk,&#xD;
             well-differentiated carcinomas of thyroid, breast or prostate that are very unlikely&#xD;
             to require further treatment in the opinion of the treating physician, or squamous&#xD;
             cell or basal cell carcinoma of the skin).&#xD;
&#xD;
          -  Clinical or radiological signs of compression of the optic chiasm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Valencia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cortendo AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keck Medical Center University of Southern California HCII, Internal Medicine - Keck Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center, Cedars-Sinai Pituitary Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine, Medicine/Endocrinology Department</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Diabetes and Endocrine Care</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Neurosurgery</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University, Medicine - Endocrinology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University, Endocrinology Department</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Comprehensive Endocrine Research, Internal Medicine - MEND</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Endocrinology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University, College of P&amp;S Medicine/Neuro-endocrine Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center, Endocrinology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University, Neurological Surgery</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Neuroendocrinology Center, West Penn Allegheny Health System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandovska University Hospital, Clinic of Endocrinology &amp; Metabolic Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Aleksandrovska&quot; EAD Clinic of Endocrinology and Metabolic Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Specialized Hospital for Active Treatment in Endocrinology (USHATE) I Klinika</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen University Hospital, Endocrinology Department</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital de la Conception, Service d'Endocrinologie, Diabète et Maladies Métaboliques</name>
      <address>
        <city>Marseille</city>
        <state>Cedex 5</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelismos Athens General Hospital, Department of Endocrinology</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens 'G. Gennimatas', Department of Endocrinology-Diabetes Centre</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens 'Laiko', &quot;National and Kapodistrian University of Athens Medical School Pathophysiology - Endocrinology&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina, Department of Endocrinology</name>
      <address>
        <city>Ioánnina</city>
        <zip>45110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital, &quot;Endocrinology and Diabetes Department</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. Belgyógyászati Klinika A.épület I.emelet ODM-labor</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center, Institute of Endocrinology</name>
      <address>
        <city>Haifa</city>
        <zip>34802</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center- Beilinson Hospital, &quot;Institute of Endocrinology &amp; Metabolism, Beilinson Campus&quot;</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center Institute of Endocrinology, Metabolism and Hypertension</name>
      <address>
        <city>Tel Aviv</city>
        <zip>642-3906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Endocrinologia e malattie del Metabolismo, Dipartimento Specialità Mediche</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Genova, Department of Internal Medicine &amp; Medical Specialties (DiMI)</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico G. Martino Sezione di Endocrinologia</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Federico II, Sezione di Endocrinologia (Edificio 1, Secondo Piano)</name>
      <address>
        <city>Napoli</city>
        <zip>8031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli, Università Cattolica del Sacro Cuore, Endocrinology</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Sant'Andrea, Scienze Mediche</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Citta della Salure e della Scienza SC Endocrinologia, Diabetologia e Metabolismo</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University, Leiden University Medical Center, Department of Endocrinology</name>
      <address>
        <city>Leiden</city>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center, Department of Internal Medicine</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Institute - Cancer Center Gliwice Branch, Nuclear Medicine and Endocrine Oncology Department</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny, Klinika Gastroenterologii, Endokrynologii I Chorob Wewnetrznych</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki, Oddział Endokrynologii i Chorób Metabolicznych</name>
      <address>
        <city>Łódź</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean Mures, Compartimentul de Endocrinologie</name>
      <address>
        <city>Târgu-Mureş</city>
        <state>Mures</state>
        <zip>540072</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta &quot;Pius Brinzeu&quot;, Departamentul de Endocrinologie</name>
      <address>
        <city>Timişoara</city>
        <state>Timis</state>
        <zip>300723</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Endocrinologie C.I. Parhon, Sectia Clinica de Endocrinologie II, Patologia tiroidei de corelatie</name>
      <address>
        <city>Bucuresti</city>
        <zip>011863</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj-Napoca, Sectia Clinica Endocrinologie</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universidad De La Ribera, Endocrinologia</name>
      <address>
        <city>Alzira</city>
        <state>Valencia</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal, Endocrinology and Nutrition</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <disposition_first_submitted>March 12, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>March 12, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 16, 2021</disposition_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cushing Syndrome, Adrenocortical Hyperfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

